About
Titles
Associate Professor of Neurology
Biography
Dr. Patel is a board-certified Neurologist with subspecialty training in Movement Disorders. He obtained his medical degree from the Mount Sinai School of Medicine, where he also completed his residency in Neurology and served as Chief Resident. He subsequently completed a 2 year fellowship in Movement Disorders at Mount Sinai Hospital. He treats patients with a variety of complex movement disorders, including Parkinson's disease, essential tremor, dystonia, tics, myoclonus and chorea. He has a particular interest in the use of Deep Brain Stimulation and botulinum toxin in the treatment of movement disorders.
Appointments
Neurology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Mount Sinai School of Medicine (2015)
- Resident
- Mount Sinai School of Medicine (2013)
- Intern
- Yale-New Haven Hospital (2010)
- MD
- Mount Sinai School of Medicine (2009)
- BS
- Yale University (2005)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0002-5242-3502
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Michael Schilsky, MD
Paula Zimbrean, MD, FAPA, FACLP
Uyen To, MD
Ricarda Tomlin
Sule Tinaz, MD, PhD
David Matuskey, MD
Deep Brain Stimulation
Parkinson Disease
Subthalamic Nucleus
Dystonia
Publications
2024
Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease
de Laat B, Hoye J, Stanley G, Hespeler M, Ligi J, Mohan V, Wooten D, Zhang X, Nguyen T, Key J, Colonna G, Huang Y, Nabulsi N, Patel A, Matuskey D, Morris E, Tinaz S. Intense exercise increases dopamine transporter and neuromelanin concentrations in the substantia nigra in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 34. PMID: 38336768, PMCID: PMC10858031, DOI: 10.1038/s41531-024-00641-1.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDopamine transporterSubstantia nigraDopaminergic neuronsDopamine transporter availabilityNeuroprotective effects of exerciseDopaminergic systemClinical progression of PDEarly PDSubstantiaNeuromelanin contentNigraLoss of dopaminergic neuronsEffects of exerciseNM-MRIDopamineSystem of patientsProgressive loss of dopaminergic neuronsParkinson's diseaseClinical progressionProgression of PDNeuroprotective effectsClinical trialsIntensity exercisePET imagingProgressive loss
2023
Differential impact of resilience on demoralization and depression in Parkinson disease
de Figueiredo J, Zhu B, Patel A, Kohn R, Koo B, Louis E. Differential impact of resilience on demoralization and depression in Parkinson disease. Frontiers In Psychiatry 2023, 14: 1207019. PMID: 37559912, PMCID: PMC10408307, DOI: 10.3389/fpsyt.2023.1207019.Peer-Reviewed Original ResearchCitationsAltmetric
2022
Major Depressive Disorder in an International Multisite Wilson Disease Registry
Camarata M, Ala A, Coskun A, Deng Y, Embel V, Gonzalez-Peralta R, Maciejewski K, Patel A, Rubman S, To U, Tomlin R, Schilsky M, Zimbrean P. Major Depressive Disorder in an International Multisite Wilson Disease Registry. Journal Of The Academy Of Consultation-Liaison Psychiatry 2022, 64: 106-117. PMID: 36521682, DOI: 10.1016/j.jaclp.2022.12.001.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsMajor depressive disorderWilson's diseaseDepressive disorderLifetime major depressive disorderMental health QOLPhysical health QoLMajor depressive episodeMental health qualityStructured psychiatric evaluationSignificant differencesCross-sectional reportsLiver testsLiver diseaseNeurological assessmentLife scoresClinical correlatesDepressive episodePsychiatric symptomsPsychiatric evaluationDisease RegistrySevere anxietyLaboratory testsLifetime historySignificant associationPatientsMental imagery content is associated with disease severity and specific brain functional connectivity changes in patients with Parkinson’s disease
Cherry J, Kamel S, Elfil M, Aravala S, Bayoumi A, Patel A, Sinha R, Tinaz S. Mental imagery content is associated with disease severity and specific brain functional connectivity changes in patients with Parkinson’s disease. Brain Imaging And Behavior 2022, 17: 161-171. PMID: 36434490, PMCID: PMC10050121, DOI: 10.1007/s11682-022-00749-z.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsImagery trainingFunctional connectivity changesMild Parkinson's diseaseVisual imagery trainingMental imagery trainingComplex cognitive processesConnectivity changesMotor imagery trainingBrain functional connectivity changesFunctional connectivity characteristicsExecutive processesMental imageryCognitive processesPerceptual experienceNeural correlatesBrain mechanismsImagery practiceImagery contentSensorimotor processesNeuropsychiatric patient populationsMotor functionMotor actsMotor enhancementBrain areasParkinson's disease
2020
P13 Major depressive disorder in patients with wilson’s disease: relationship with liver disease, neurological disease and quality of life
Camarata M, Ala A, Maciejewski K, To U, Zimbrean P, Rubman S, Patel A, Wadhwa A, Coskun A, Apdik T, Tomlin R, Deng Y, Schilsky M. P13 Major depressive disorder in patients with wilson’s disease: relationship with liver disease, neurological disease and quality of life. Gut 2020, 69: a13-a13. DOI: 10.1136/gutjnl-2020-basl.24.Peer-Reviewed Original ResearchConceptsMajor depressive disorderQuality of lifeMental health QOLWilson's diseaseNeurological diseasesLiver diseaseDepressive disorderFirst presentationExact testDepression symptomologySeverity of liverLifetime major depressive disorderLiver disease severityFisher's exact testPhysical health QOLSignificant differencesWilcoxon rank sum testMental health problemsRank sum testFIB4 scoreClinical featuresNeurological assessmentPHQ-9PatientsCurrent depressionP12 Effect of liver disease, neurological disease and mental health issues on quality of life in patients with wilson disease
Camarata M, Ala A, Maciejewski K, To U, Zimbrean P, Rubman S, Coskun A, Patel A, Wadhwa A, Apdik T, Tomlin R, Deng Y, Gonzalez-Peralta R, Schilsky M. P12 Effect of liver disease, neurological disease and mental health issues on quality of life in patients with wilson disease. Gut 2020, 69: a13-a13. DOI: 10.1136/gutjnl-2020-basl.23.Peer-Reviewed Original ResearchConceptsMental health issuesWilson's diseaseHealth issuesSeverity of liverMental health QOLPhysical health QoLReview of imagingP-QOL scoresQuality of lifeFIB4 scoreAdult patientsRegistry studyNeurological assessmentPhysical health issuesChronic diseasesOutcome measuresPatientsNeurological diseasesWD patientsQoLAssess qualityDiseaseCirrhosisSignificant differencesScoresFRI303 Major depressive disorder in patients with Wilson’s disease: relationship with liver disease, neurological disease and quality of life
Camarata M, Ala A, To U, Zimbrean P, Rubman S, Patel A, Wadhwa A, Maciejewski K, Song X, Deng Y, Tomlin R, Apdik T, Coskun A, Schilsky M. FRI303 Major depressive disorder in patients with Wilson’s disease: relationship with liver disease, neurological disease and quality of life. Journal Of Hepatology 2020, 73: s550-s551. DOI: 10.1016/s0168-8278(20)31573-7.Peer-Reviewed Original ResearchDeep Brain Stimulation Target Selection in Co-Morbid Essential Tremor and Parkinson’s Disease
Wadhwa A, Schaefer S, Gerrard J, Deeb W, Okun MS, Patel A. Deep Brain Stimulation Target Selection in Co-Morbid Essential Tremor and Parkinson’s Disease. Tremor And Other Hyperkinetic Movements 2020, 10: 17. PMID: 32775031, PMCID: PMC7394224, DOI: 10.5334/tohm.62.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsDeep brain stimulationParkinson's diseaseEssential tremorHead trialsDBS targetsAction tremorSubthalamic nucleus (STN) DBSThalamus deep brain stimulationLimited evidenceDBS target selectionVentral intermediate nucleusBilateral STNPD patientsDBS treatmentEquivalent efficacyRest tremorMild improvementCurrent evidenceET patientsET tremorBrain stimulationComparative efficacyPatientsExpert consensusTremor reduction257 Bipolar disorder in patients with Wilson disease
Zimbrean P, Rubman S, Maciejewski K, Coskun, Nalamada K, Camarata M, Tomlin R, Patel A, To U, Ala A, Gonzalez-Peralta R, Deng Y, Schilsky M. 257 Bipolar disorder in patients with Wilson disease. Journal Of Psychosomatic Research 2020, 133: 110055. DOI: 10.1016/j.jpsychores.2020.110055.Peer-Reviewed Original Research
2019
Dorsal GPi/GPe Stimulation Induced Dyskinesia in a Patient with Parkinson’s Disease
Elkouzi A, Tsuboi T, Burns M, Eisinger R, Patel A, Deeb W. Dorsal GPi/GPe Stimulation Induced Dyskinesia in a Patient with Parkinson’s Disease. Tremor And Other Hyperkinetic Movements 2019, 9 DOI: 10.5334/tohm.496.Peer-Reviewed Original ResearchCitationsConceptsStimulation-induced dyskinesiasParkinson's diseaseGPi DBSBilateral GPi DBSGPi stimulationMotor fluctuationsPD patientsTherapeutic benefitSide effectsVentral contactVolume of tissuePatientsDiseaseMore studiesDyskinesiaMotor controlDiffusion tensorSpecific tractsPotential strategyStimulationTherapyTractMRI
Clinical Trials
Current Trials
A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease (GATEWAY)
HIC ID2000028887RoleSub InvestigatorPrimary Completion Date07/31/2023Recruiting ParticipantsGenderBothAge18 years - 60 yearsWilson Disease Registry
HIC ID1609018429REGRoleSub InvestigatorPrimary Completion Date10/01/2022Recruiting ParticipantsGenderBoth
Academic Achievements & Community Involvement
activity American Academy of Neurology
Professional OrganizationsMemberDetails2009 - Presentactivity International Parkinson and Movement Disorder Society
Professional OrganizationsMemberDetails07/01/2013 - Presenthonor Morris Bender Award for Clinical Neurology
Regional AwardMount Sinai School of MedicineDetails04/01/2009United Stateshonor William R. Belknap Senior Prize in Biology
Yale University AwardYale UniversityDetails05/23/2005United Stateshonor Phi Beta Kappa
Yale University AwardYale UniversityDetails12/01/2004United States
Clinical Care
Overview
Amar Patel, MD, treats patients with a variety of complex movement disorders, and has a particular interest in Parkinson’s disease, a brain disorder of the central nervous system that can cause tremors, stiffness or slowing of movement. “Current and future therapies offer patients with Parkinson’s disease the chance to maintain their quality of life,” he says.
An assistant professor of neurology at Yale School of Medicine, Dr. Patel says he was drawn to his field by “the chance to intervene when an often devastating neurological illness impairs a patient’s quality of life.” As a researcher, he is examining the use of deep brain stimulation and botulinum toxin in the treatment of movement disorders.
Clinical Specialties
Fact Sheets
Pediatric Movement Disorders
Learn More on Yale MedicineDystonia
Learn More on Yale MedicineStiff Person Syndrome (SPS)
Learn More on Yale MedicineHuntington's Disease
Learn More on Yale Medicine
Board Certifications
Neurology
- Certification Organization
- AB of Psychiatry & Neurology
- Original Certification Date
- 2013
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileNews & Links
News
Related Links
Get In Touch
Contacts
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.